Mirum Pharmaceuticals Inc Cash Flow Conversion Efficiency
Mirum Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Mirum Pharmaceuticals Inc (MIRM) has a cash flow conversion efficiency ratio of -0.943x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-228.76 Million) by net assets ($242.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Mirum Pharmaceuticals Inc (2018–2025)
Cash flow conversion efficiency of Mirum Pharmaceuticals Inc from 2018 to 2025. This chart illustrates how Mirum Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MIRM stock price and chart for real-time trading data and today's change.
Mirum Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Mirum Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Mirum Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mirum Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see MIRM company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WinWay Technology Co. Ltd
TW:6515
|
0.020x |
|
Vipshop Holdings Limited
NYSE:VIPS
|
N/A |
|
Kite Realty Group Trust
NYSE:KRG
|
0.033x |
|
China Greatwall Computer Shenzhen Co Ltd
SHE:000066
|
-0.002x |
|
Amlogic Shanghai Co Ltd
SHG:688099
|
0.051x |
|
ViTrox Corporation Bhd
KLSE:0097
|
0.029x |
|
CSN Mineração S.A
SA:CMIN3
|
0.096x |
|
EVN AG
VI:EVN
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Mirum Pharmaceuticals Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Mirum Pharmaceuticals Inc from 2018 to 2025. Review cash generation quality of Mirum Pharmaceuticals Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $314.69 Million | $55.83 Million | 0.177x | +287.69% |
| 2024-12-31 | $225.64 Million | $10.32 Million | 0.046x | +116.04% |
| 2023-12-31 | $248.67 Million | $-70.94 Million | -0.285x | +66.27% |
| 2022-12-31 | $142.04 Million | $-120.14 Million | -0.846x | +23.41% |
| 2021-12-31 | $120.21 Million | $-132.76 Million | -1.104x | -113.37% |
| 2020-12-31 | $172.09 Million | $-89.08 Million | -0.518x | -71.40% |
| 2019-12-31 | $130.35 Million | $-39.36 Million | -0.302x | -935.73% |
| 2018-12-31 | $-10.32 Million | $-373.00K | 0.036x | -- |
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille … Read more